asston pharmaceuticals limited

asston pharmaceuticals limited

APL • ISIN: INE0SJX01015

BSE
SME

Listing Price: ₹119

-3.25% Loss
About Company

Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.

The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.

The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.

The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.

Products:


Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
Ferrovit Syrup: To treat vitamin and mineral deficiencies.


As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.

Competitive Strengths:


Formulation Expertise
Experienced Promoters
Wide range of Products
Strategic Location
Skilled Workforce

Investment Objective

Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit

Funding the incremental working capital requirements of the Company

Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company

General Corporate Purposes

₹123

Price Band

1.23 L

Min Investment

1000 shares

Lot Size

13.2x

P/E Ratio

Important Dates

Issue Opens

9 Jul 2025

Issue Closes

11 Jul 2025

Allotment

14 Jul 2025

Listing

16 Jul 2025

Subscription Status
QII

Qualified Institutional Investors

34.39x

36,449,000 / 1,060,000 shares

HNI (>₹10L)

High Networth Individuals (Above ₹10 Lakhs)

424.47x

91,262,000 / 215,000 shares

NII (<₹10L)

Non-Institutional Investors (Below ₹10 Lakhs)

210.88x

22,564,000 / 107,000 shares

Retail

Retail Individual Investors

172.14x

128,416,000 / 746,000 shares

Financial Performance
Offer Documents
RHP
Visit
DHRP
Visit
Issue Details
Issue TypeBB
Face Value₹10
Lead ManagersSobhagya Capital Options Ltd
Min Quantity2,000
Max Quantity4,065
Company Promoters
Dr. Ashish Narayan Sakalkar
Saili Jayaram
Website

http://www.asstonpharmaceuticals.com/

Email

info@asstonpharmaceuticals.com

Phone+91 22 49731411
Address

Asston Pharmaceuticals Ltd.
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614